Edgestream Partners L.P. Sells 17,303 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Edgestream Partners L.P. lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 74.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,052 shares of the biopharmaceutical company’s stock after selling 17,303 shares during the quarter. Edgestream Partners L.P.’s holdings in Alnylam Pharmaceuticals were worth $1,471,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Capital International Investors increased its stake in Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after purchasing an additional 488,814 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares in the last quarter. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after acquiring an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after acquiring an additional 201,784 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth $18,886,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALNY. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday. Finally, BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Down 0.9 %

NASDAQ ALNY opened at $273.88 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The company has a market cap of $34.64 billion, a PE ratio of -102.19 and a beta of 0.38. The firm’s 50-day simple moving average is $260.11 and its two-hundred day simple moving average is $198.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. During the same period in the previous year, the company posted ($2.21) earnings per share. The company’s quarterly revenue was up 107.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.